PRCP is a promising drug target for intracranial aneurysm rupture supported via multi-omics analysis

• Published in: Stroke and vascular neurology p. svn-2023-003076
• Main Authors: Wu, Jinghao, Mei, Yunyun, Li, XinYu, Yu, Wen-Kai, Zhou, Zi Han, Yang, Yinghao, Niu, Pengpeng, Wang, Yunchao, Shi, Chang-He, Zhu, Hanghang, He, Wenjun, Gao, Yuan, Xu, Yuming, Li, Yusheng
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd 24.08.2024; BMJ Publishing Group LTD; BMJ Publishing Group
• Subjects: Aneurysms; Clinical trials; Consortia; Disease; Genes; Genomes; Hemorrhage; Intracranial Aneurysm; Original research; Proteins; Software; Stroke; Intracranial Aneurysm; Hemorrhage; Stroke
• ISSN: 2059-8688; 2059-8696; 2059-8696
• DOI: 10.1136/svn-2023-003076

BackgroundCerebral aneurysms are life-threatening cerebrovascular disorders. Currently, there are no effective treatments for preventing disease progression. Mendelian randomisation (MR) is widely used to repurify licensed drugs and identify new therapeutic targets. Therefore, this study aims to investigate effective drug targets for preventing the formation and rupture of cerebral aneurysms and analyse their potential mechanisms.MethodsWe performed a comprehensive study integrating two-sample MR analysis, colocalisation analysis and summary data-based Mendelian randomisation (SMR) to assess the causal effects of blood and brain druggable cis-expression quantitative trait loci (cis-eQTLs) on intracranial aneurysm (IA), unruptured intracranial aneurysm (UIA) and subarachnoid haemorrhage of IA rupture (SAH). Druggable genes were obtained from the study by Chris Finan et al, cis-eQTLs from the eQTLGen and PsychENCODE consortia. Results were validated using proteomic and transcriptomic data. Single-gene functional analyses probed potential mechanisms, culminating in the construction of a drug-gene regulation network.ResultsThrough the MR analysis, we identified four potential drug targets in the blood, including prolylcarboxypeptidase (PRCP), proteasome 20S subunit alpha 4 (PSMA4), LTBP4 and GPR160 for SAH. Furthermore, two potential drug targets (PSMA4 and SLC22A4) were identified for IA and one potential drug target (KL) for UIA after accounting for multiple testing (P(inverse-variance weighted)<8.28e-6). Strong evidence of colocalisation and SMR analysis confirmed the relevance of PSMA4 and PRCP in outcomes. Elevated PRCP circulating proteins correlated with a lower SAH risk. PRCP gene expression was significantly downregulated in the disease cohort.ConclusionsThis study supports that elevated PRCP gene expression in blood is causally associated with the decreased risk of IA rupture. Conversely, increased PSMA4 expression in the blood is causally related to an increased risk of IA rupture and formation.